- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Bruce Sherman, MD, FCCP, FACOEM: Biosimilars and Costs for Employers
Bruce Sherman, MD, FCCP, FACOEM, chief medical officer of the National Alliance for Healthcare Purchaser Coalitions, discusses how biosimilars will play a role in controlling high drug costs for employers.
Transcript
I think biosimilars will be helpful. I think there’s a little doubt from a cost standpoint. I think the willingness to embrace biosimilars in the [United States] has been slower than what we’ve seen, for example, in Europe, but I think they are here to stay. Hopefully the additional competition will help to further contribute to lower drug prices, and I think it’s just going to be a matter of time before those drugs are more readily available.
I think, though, we also have to appreciate the significance not only of the drug but of the support services that may be coming from the respective pharmaceutical manufacturers that represent a wraparound offering for the specialty drugs that they manufacture. If those programs are providing additional value, I would hope that the biosimilar manufacturers could provide something comparable to those as well.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
